
https://www.science.org/content/blog-post/retraction-ten-years-later
# A Retraction, Ten Years Later (June 2015)

## 1. SUMMARY

The article reports on a retraction notice from Organic Letters concerning a 2004 paper by the Baldwin research group at Oxford University titled "Biomimetic Synthesis of Himbacine." The retraction was issued because subsequent replication attempts revealed that spectra data for compound 14 (a linear precursor) differed from the originally published results, and spectra for several derived compounds (3, 4, and 20) were found to have been scanned from an earlier synthesis paper by Chackalamannil et al. The Baldwin group paper had four authors: Jack Baldwin, Kirill Tchabanenko, Robert Adlington, and Andrew R. Cowley. The author notes this appears to be a case of research misconduct involving copied spectral data, though the specific details and responsible party remain unclear.

## 2. HISTORY

This retraction represents one data point in the broader pattern of research misconduct cases in chemistry during the 2010s. What happened subsequent to this 2015 article includes:

The Baldwin group retraction joined a growing list of chemistry papers retracted due to fabricated or manipulated spectral data, part of a concerning trend that prompted increased scrutiny of analytical data in organic chemistry publications. After 2015, major chemistry journals implemented more rigorous data verification processes and began requiring raw NMR files for review.

Jack Baldwin (1938-2024), a highly respected chemist and former head of organic chemistry at Oxford, maintained his reputation despite this retraction occurring under his oversight. The incident did not appear to significantly impact his standing in the chemistry community, suggesting it was viewed as an isolated case rather than indicative of systemic issues in his laboratory.

Kirill Tchabanenko continued his academic career, becoming a lecturer at Queen's University Belfast, indicating the retraction did not end his professional trajectory in chemistry.

The broader context is that himbacine (the target molecule in question) continued to be studied for its muscarinic receptor antagonist properties, though it has not led to any FDA-approved drugs. The compound has remained primarily of academic interest in medicinal chemistry research.

## 3. PREDICTIONS

The original 2015 article did not contain specific predictions about the futureâ€”it was primarily reporting on a retraction that had already occurred and speculating about the unknown circumstances behind the misconduct. The author's main commentary focused on the "nerve" required to scan spectra from other papers and pass them off as original data.

## 4. INTEREST

**Rating: 2/10**

This article has limited long-term significance as it reports on a single research misconduct case of narrow scope. While research integrity is important, this particular incident did not have broader implications for the biotechnology industry or scientific policy, and himbacine has not emerged as a therapeutically important compound.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20150622-retraction-ten-years-later.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_